Libtayo® (cemiplimab-rwlc) – New indication
February 22, 2021, Regeneron announced the FDA approval of Libtayo (cemiplimab-rwlc), for the first-line treatment of patients with non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (tumor proportion score [TPS] ≥ 50%) as determined by an FDA-approved test with no EGFR, ALK or ROS1 aberrations, and is locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic.
Top